P

Parallel Biosystems

AI-assisted immune organoid drug discovery platform

IT/OT Specialist

Full-Time
$145k - $165k/yr
Mid, Senior
San Francisco, CA, USA
In PersonFull-time on-site work is required at the San Francisco and Brisbane, California labs.
IT OperationsSystem Administration

About the job

Requirements
  • Three to six years of experience in IT infrastructure, systems administration, or a related role, including OT experience with industrial or lab device networking or hardware integration.
  • Solid grounding in networking, identity and access management, and endpoint management.
  • Experience building processes in an environment where they were still being developed.
  • Ability to troubleshoot technical issues and serve as a point of contact when systems break.
  • Ability to discuss system design with technical colleagues and explain issues to scientists who do not need technical detail.
  • Willingness and ability to work consistently on-site and be physically present for hands-on troubleshooting.
Responsibilities
  • Support network and connectivity needs for lab instrumentation and automation equipment, including integrating devices onto secure, segmented networks.
  • Partner with the Platform/Automation team and Cloud Architect to troubleshoot connectivity and data-flow issues between instruments, automation systems, and the cloud data platform.
  • Maintain an inventory of connected lab devices, their configurations, and their support and service status.
  • Help define and implement basic OT security practices, including network segmentation and access control for instrument systems, in coordination with IT security.
  • Support integration of new instrumentation as the platform scales, working alongside automation engineers and platform leadership.
  • Maintain the equipment register by tracking each connected lab device's owner, location, readiness, and service or calibration status, and keep it current as new equipment comes online.
  • Follow lab safety and access protocols, including badge access and applicable PPE requirements, when working in or near BSL-2+ lab areas.
  • Support day-to-day IT operations, including user accounts, identity and access management, endpoint provisioning, and helpdesk support across sites.
  • Support maintenance of core infrastructure, including networking, servers, cloud accounts, backups, and security tooling, coordinating with the Cloud Architect on architecture and cloud-side decisions.
  • Support implementation and enforcement of IT security practices, including access controls, patching, and monitoring, working with Legal/Compliance on information security and data privacy requirements as they are established.
  • Support onboarding and offboarding for a growing, multi-site team.
  • Support evaluation, deployment, and maintenance of company software tools, including collaboration tools and LIMS-adjacent systems.
  • Maintain documentation for IT systems, configurations, and processes.
  • Provide on-call support for critical IT/OT issues, including lab-impacting outages outside normal business hours.
Desired Qualifications
  • Experience in a life sciences, biotech, or laboratory environment.
  • Familiarity with LIMS, instrument data systems, or laboratory networks.

About the company

Parallel Biosystems provides a drug discovery platform that uses immune organoids, artificial intelligence (AI), and robotics to model human diseases and develop immunotherapies. It offers services to pharmaceutical companies, biotech firms, and research institutions, charging service fees, licensing, and milestone payments. The platform works by growing miniaturized human immune organoids in the lab, applying AI to analyze results and guide experiments, and using robotics to automate workflows, enabling faster, cheaper, and more accurate drug discovery than traditional methods. What sets Parallel Biosystems apart is its combination of human-relevant organoid models with AI analytics and automated lab systems, aiming to produce therapies that work across diverse populations. The company’s goal is to accelerate the development of safer and more effective drugs, speeding therapies from research to patients and expanding options for cancer, autoimmune, and age-related diseases.

Company Size

11-50

Company Stage

Series A

Total Funding

$25.4M

Headquarters

Brisbane, California

Founded

2020

Get referred to Parallel Biosystems

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • June 16, 2026 Bay Area consolidation strengthens hiring and execution speed.
  • World Economic Forum named Parallel Bio a 2026 Technology Pioneer, boosting credibility.
  • In-house drug development started February 2026, creating higher-upside proprietary programs.

What critics are saying

  • Parallel Bio raised only $21 million Series A on June 12, 2025; runway tight.
  • Organoid workflows face entrenched competition from CN Bio, Mimetas, and Isomorphic Labs.
  • If FDA ignores organoid evidence, pharmaceutical customers stay experimental and Parallel Bio's platform stalls.

What makes Parallel Biosystems unique

  • Parallel Bio unites immune organoids, robotics, and AI for human biology modeling.
  • June 16, 2026 headquarters consolidation merges biology and computation in Brisbane, speeding iteration.
  • Eight pharma partners, including three Fortune 500s, tested 50-plus drugs and immunotherapies.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

-11%

1 year growth

4%

2 year growth

4%
HealthTech HotSpot
Jun 16th, 2026
Parallel Bio establishes San Francisco Bay Area as U.S. Headquarters, appoints five industry leaders to advisory board.

Parallel Bio establishes San Francisco Bay Area as U.S. Headquarters, appoints five industry leaders to advisory board. * Parallel Bio returns to Bay Area roots, bringing computational and biological operations under one roof * New advisors strengthen leadership in immunology, AI, drug development and cybersecurity SAN FRANCISCO-(BUSINESS WIRE)-Parallel Bio, a biotech company pioneering human-first drug discovery, today announced it is centering U.S. operations at its San Francisco Bay Area headquarters in Brisbane, CA, bringing computational and biological functions together in one location. The move builds on Parallel Bio's Bay Area foundation, as co-founders Robert DiFazio and Juliana Hilliard founded the company in San Francisco in 2021. At the time, DiFazio worked at Stanford University, directing an interdisciplinary institute of over 150 faculty studying human immunology, and Hilliard worked at Herophilus (formerly known as System1), adapting brain organoid technology for high-throughput drug discovery. The company is backed by Bay Area investors including AIX Ventures, which led Parallel Bio's $21 million Series A round; Marc Benioff, founder and CEO of Salesforce; Jeff Dean, head of Google DeepMind; Y Combinator; and other biotech and deeptech funds. Parallel Bio also announced five new advisors as the company scales its platform and partnerships across multiple therapeutic areas: * Shane Crotty, Professor and Chief Scientific Officer at one of the world's leading institutes of human immunology * Ron Philip, former CEO of Orbital Therapeutics and Spark Therapeutics * Andre Esteva, CEO and co-founder of ArteraAI * Rick Bright, PhD, CEO of Bright Global Health and former Director of BARDA * Jason Kichen, Chief Information Security Officer of Fluidstack and adjunct faculty at the University of California, Berkeley. "For decades, the pharmaceutical industry has sought better ways to evaluate therapies in human biology before advancing into clinical studies. Parallel Bio is taking an important step toward addressing that challenge," said Philip. "I joined the advisory board because I believe their platform has the potential to meaningfully improve how new medicines are developed." These advisors bring deep experience across the company's core focus areas including human immunology, drug development, AI for medicine, and data infrastructure, positioning Parallel Bio to lead the transformation of drug development as the industry moves beyond animal testing. "We're fortunate to add these five exceptional advisors whose expertise will be invaluable as we scale our platform and partnerships," said DiFazio. "Likewise, bringing our team together in the Bay Area allows us to move faster and integrate our computational and biology work more tightly." With the move, Parallel Bio is actively recruiting scientific and engineering talent across the Bay Area. The company currently works with numerous pharmaceutical partners, including three Fortune 500 companies, who are testing more than 50 drugs and immunotherapies using Parallel Bio's organoid-based immune system modeling platform. "The Bay Area has always been our home, and this consolidation positions us to build on that foundation," said Hilliard. "We're excited to grow our team here and continue advancing human-first drug discovery with support from some of the world's leading experts in immunology, AI, and biotech." About Parallel Bio Parallel Bio is pioneering human-first drug discovery by creating the first map of human biology. The company generates data using groundbreaking biological and computational tools that track real clinical outcomes, enabling earlier, more reliable decisions about disease biology and drug discovery. The platform overcomes the core limitations of traditional animal testing, which almost always fails to predict how drugs will behave in people. Parallel Bio is building its own drug discovery pipeline in cancer and autoimmune disease while collaborating with pharmaceutical companies to evaluate therapies directly in human systems before costly and risky clinical trials. Founded in 2021 by two scientists with deep expertise in cutting-edge human models, Parallel Bio is backed by leading investors in AI and biotech, including AIX Ventures, Marc Benioff, and Jeff Dean. Learn more at parallel.bio.

Business Wire
Jun 16th, 2026
Parallel Bio consolidates US ops in San Francisco, adds five advisors including ex-Spark CEO

Parallel Bio, a biotech company pioneering human-first drug discovery, has established its US headquarters in Brisbane, California, consolidating computational and biological operations in the San Francisco Bay Area. The company was founded in San Francisco in 2021 by Robert DiFazio and Juliana Hilliard. The move accompanies the appointment of five industry leaders to its advisory board, including Shane Crotty, Ron Philip, Andre Esteva, Rick Bright and Jason Kichen. These advisors bring expertise across human immunology, drug development, AI for medicine and data infrastructure. Parallel Bio is backed by Bay Area investors including AIX Ventures, which led its $21 million Series A round, alongside Marc Benioff and Jeff Dean. The company currently works with pharmaceutical partners, including three Fortune 500 companies, testing over 50 drugs using its organoid-based immune system modelling platform.

Silverwood Partners
Jun 18th, 2025
Healthcare Private Placement and M&A Transactions Review Week Ending June 15, 2025

iView Therapeutics: The company raised $9.2 million of Series A venture funding in a deal led by Chongqing Dian Petrochemical Medical Fund Management on February 24, 2025.

Endpoints News
Jun 11th, 2025
Parallel Bio raises $21M for lymph node tech

Parallel Bio, a startup that has developed a method to grow miniature human lymph nodes in a dish, has secured $21 million in Series A funding.

Endpoints News
Jun 11th, 2025
Exclusive: Organoid startup raises $21M to test drugs and vaccines in human lymph nodes-in-a-dish

Parallel Bio, a startup that figured out how to grow miniature human lymph nodes in a dish, has raised $21 million in Series A funding...